Latest news with #AIMImmunoTechInc
Yahoo
2 days ago
- Business
- Yahoo
AIM ImmunoTech Announces 1-for-100 Reverse Stock Split
OCALA, Fla., June 11, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (OTC Pink: AIMID) (NYSE American: AIM) ('AIM' or the 'Company') today announced a reverse stock split ('Reverse Stock Split') of its shares at a ratio of 1-for-100. The Reverse Stock Split will take effect at market open tomorrow, June 12, 2025. The Company's ticker symbol on the OTC Pink will be AIMID for 20 trading days, including the effective date. One of the primary goals of the Reverse Stock Split is to increase the per-share market price of the Company's common stock to enable the Company to regain compliance with the NYSE American's Listing Qualifications. At a Special Meeting of Stockholders held on April 30, 2025, the Company's stockholders approved a series of alternate amendments to the Company's Certificate of Incorporation to effect a reverse stock split of the Company's outstanding common stock at a ratio in the range of up to 1-for-100, with such ratio to be determined by the Company's Board of Directors. Stockholders will be given cash in lieu of any fractional shares on a post-split basis. Following the Reverse Stock Split, the new CUSIP number of the common stock will be 00901B303, with the par value per share of common stock remaining at $0.001. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy in any indication. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. CONTACT: Investor Contact: JTC Team, LLC Jenene Thomas 908.824.0775 AIM@
Yahoo
02-04-2025
- Business
- Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
Cash, Cash Equivalents, and Marketable Securities: Approximately $4 million as of December 31, 2024. Research and Development Expenses: $6.2 million for the year ended December 31, 2024, compared to $10.9 million for the year ended December 31, 2023. General and Administrative Expenses: $13.7 million for the year ended December 31, 2024, compared to $21.1 million for the year ended December 31, 2023. Warning! GuruFocus has detected 6 Warning Signs with AIM. Release Date: April 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. AIM ImmunoTech Inc (AIM) announced a new clinical study evaluating Ampligen in combination with AstraZeneca's FluMist as a potential intranasal vaccine for influenza, including avian flu. The company strengthened its leadership team by adding two experienced Board members, Ted Kellner and David Chemerow, to guide strategic execution. The Erasmus Medical Center Safety Committee approved the continuation into the Phase 2 portion of the DURIPANC pancreatic cancer trial, marking progress in their clinical programs. AIM ImmunoTech Inc (AIM) reported final clinical results from the AMP-518 study, reinforcing Ampligen's potential in treating post-COVID conditions. The company expanded its intellectual property estate with new patents in the US and Netherlands, enhancing protection for Ampligen's applications. AIM ImmunoTech Inc (AIM) reported a decrease in cash, cash equivalents, and marketable securities to approximately $4 million as of December 31, 2024. Research and development expenses decreased from $10.9 million in 2023 to $6.2 million in 2024, indicating potential budget constraints. General and administrative expenses also decreased from $21.1 million in 2023 to $13.7 million in 2024, which may reflect cost-cutting measures. The company is facing challenges in maintaining its listing on the New York Stock Exchange American and is considering a reverse stock split to avoid delisting. Future clinical trials will require additional manufacturing of Ampligen, which necessitates capital investment and could pose a financial challenge. Q: Do you have adequate supply of Ampligen for all your clinical trials this year, and how easy would it be to get new supply? A: Thomas Equels, President, CEO, and Executive Vice Chairman, responded that they have a budget for Ampligen tied to ongoing clinical activities, ensuring sufficient supply for current trials. For future trials, manufacturing more Ampligen will require capital, but they are actively working with polymer manufacturers and other vendors to ensure a steady supply. They do not anticipate any supply issues unless unforeseen circumstances arise. Q: What are the financial highlights for AIM ImmunoTech for the year ended December 31, 2024? A: Thomas Equels noted that AIM ImmunoTech had approximately $4 million in cash, cash equivalents, and marketable securities as of December 31, 2024. Research and development expenses were $6.2 million, down from $10.9 million in 2023. General and administrative expenses were $13.7 million, compared to $21.1 million in 2023. Q: What steps are being taken to maintain AIM ImmunoTech's listing on the New York Stock Exchange American? A: Thomas Equels emphasized that maintaining the listing is a major priority. They are evaluating all available options to maintain compliance, including a potential reverse stock split. A special meeting of stockholders will be held to authorize the Board to effect the reverse stock split to avoid delisting. Q: Can you provide an update on the DURIPANC pancreatic cancer trial? A: Thomas Equels stated that the Erasmus Medical Center Safety Committee has approved the continuation into the Phase 2 portion of the DURIPANC trial, which evaluates Ampligen in combination with AstraZeneca's Imfinzi. Dosing for Phase 2 has commenced, and they anticipate enrolling the final patient by the second or third quarter of 2026. Q: What are the upcoming milestones for AIM ImmunoTech's clinical programs? A: Thomas Equels highlighted several milestones, including the completion of a Phase 2 study in advanced ovarian cancer in the first half of 2025, the dosing of the first patient in a refractory melanoma study in the first half of 2025, and the completion of enrollment for a Stage 4 triple negative breast cancer trial by the second quarter of 2026. They are also planning a follow-up study for long COVID and a new clinical study evaluating Ampligen with FluMist for influenza. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
28-02-2025
- Health
- Associated Press
AIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenza
OCALA, Fla., Feb. 28, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) ('AIM' or the 'Company') today announced that Paul Goepfert, MD, of the University of Alabama-Birmingham ('UAB'), has agreed to act as the Principal Investigator for the company's planned clinical study in the combination of Ampligen and AstraZeneca's FluMist as an intranasal vaccine for influenza, including avian influenza. Ampligen would serve as a vaccine adjuvant. This will be a follow-up study to a previous clinical trial at UAB, which indicated that intranasal delivery of Ampligen after the intranasal delivery of the FluMist seasonal influenza vaccine not only increased the immune response to seasonal variants in the vaccine by greater than four-fold, but most importantly induced cross-reactive secretory Immunoglobulin A against highly pathogenic avian influenza virus strains H5N1, H7N9 and H7N3. Paul Goepfert, MD, Director for the Alabama Vaccine Research Clinic, stated: 'I'm excited for the opportunity to follow-up on my previous work regarding the combination of Ampligen and FluMist, especially with the rising threat of avian influenza.' AIM has engaged Amarex Clinical Research, its Clinical Research Organization, with the preparation of an Investigational New Drug application and the eventual management of the planned clinical study. A key next step will be to identify study funding through industry or governmental grants. AIM CEO Thomas K. Equels states: 'Our strong belief in the potential of a second Ampligen and FluMist study in humans stems directly from the pre-clinical and clinical work performed with Ampligen and multiple influenza variants, including in the original UAB study. We believe that the U.S. government — which has made the growing threat of avian influenza a top priority — should take a long and close look at this data when deciding how best to prepare for a potential epidemic. Rather than spend perhaps billions of dollars on the lengthy development of a new mRNA vaccine, the government should instead consider the combination of Ampligen and FluMist, which would be no more than $10 million in development costs and far quicker to develop, since it already has strong human and non-human primate data suggesting its potential preventive efficacy against avian influenza. AIM believes that the potential for a rapidly deployable vaccine that includes Ampligen is clear.' Read more about the Ampligen-involved avian influenza pre-clinical and clinical work here. About AIM ImmunoTech Inc. AIM ImmunoTech Inc., an Ocala, Florida-based company, is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the 'PSLRA'). Words such as 'may,' 'will,' 'expect,' 'plan,' 'anticipate,' 'continue,' 'believe,' 'potential,' 'upcoming' and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date do not guarantee that Ampligen will be approved as a therapy or vaccine adjuvant for any variant of influenza. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.
